In yesterday’s Wall Street session, Marker Therapeutics Inc. (NASDAQ:MRKR) shares traded at $0.34, up 1.52% from the previous session.
As of this writing, 1 analysts cover Marker Therapeutics Inc. (NASDAQ:MRKR). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $1.50 and a low of $1.50, we find $1.50. Given the previous closing price of $0.33, this indicates a potential upside of 354.55 percent. MRKR stock price is now 6.88% away from the 50-day moving average and -3.15% away from the 200-day moving average. The market capitalization of the company currently stands at $27.71M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
There are 0 analysts who have given it a hold rating, whereas 1 have given it a buy rating. Brokers who have rated the stock have averaged $1.50 as their price target over the next twelve months.
With the price target of $6, Piper Sandler recently initiated with Overweight rating for Marker Therapeutics Inc. (NASDAQ: MRKR). On March 19, 2021, Cantor Fitzgerald recently initiated its ‘Overweight’ rating on the stock quoting a target price of $6, while ‘Piper Sandler’ rates the stock as ‘Neutral’.
Insiders disposed of 117,917 shares of company stock worth roughly $40091.780000000006 over the past 1 year. A total of 13.49% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in MRKR stock. A new stake in Marker Therapeutics Inc. shares was purchased by RAYMOND JAMES & ASSOCIATES during the first quarter worth $31,000. SUSQUEHANNA INTERNATIONAL GROUP, LLP invested $5,000 in shares of MRKR during the first quarter. In total, there are 58 active investors with 25.10% ownership of the company’s stock.
Monday morning saw Marker Therapeutics Inc. (NASDAQ: MRKR) opened at $0.3305. During the past 12 months, Marker Therapeutics Inc. has had a low of $0.22 and a high of $0.73. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 2.00, and a quick ratio of 2.00. The fifty day moving average price for MRKR is $0.3122 and a two-hundred day moving average price translates $0.3456 for the stock.
The latest earnings results from Marker Therapeutics Inc. (NASDAQ: MRKR) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.11, beating analysts’ expectations of -$0.13 by 0.02. This compares to -$0.15 EPS in the same period last year. For the current quarter, analysts expect MRKR to generate $270k in revenue.
Marker Therapeutics Inc.(MRKR) Company Profile
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company’s MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.